Abstract
Acute kidney injury (AKI) is a clinical syndrome with high morbidity and mortality but no specific therapy. Microsomal prostaglandin E synthase-2 (mPGES-2) is a PGE2 synthase but can metabolize PGH2 to malondialdehyde by forming a complex with heme. However, the role and mechanism of action of mPGES-2 in AKI remain unclear. To examine the role of mPGES-2, both global and tubule-specific mPGES-2-deficient mice were treated with cisplatin to induce AKI. mPGES-2 knockdown or overexpressing HK-2 cells were exposed to cisplatin to cause acute renal tubular cell injury. The mPGES-2 inhibitor SZ0232 was used to test the translational potential of targeting mPGES-2 in treating AKI. Additionally, mice were subjected to unilateral renal ischemia/reperfusion to further validate the effect of mPGES-2 on AKI. Interestingly, both genetic and pharmacological blockage of mPGES-2 led to decreased renal dysfunction and morphological damage induced by cisplatin and unilateral renal ischemia/reperfusion. Mechanistic exploration indicated that mPGES-2 deficiency inhibited ferroptosis via the heme-dependent regulation of the p53/SLC7A11/GPX4 axis. The present study indicates that mPGES-2 blockage may be a promising therapeutic strategy for AKI.
Similar content being viewed by others
Introduction
Acute kidney injury (AKI), characterized by a sudden loss of renal function, is a common clinical complication affecting 5% to 10% of hospitalized patients and up to 60% of patients admitted to the intensive care unit [1]. Clinically, AKI can be induced by insults such as ischemia/reperfusion injury, sepsis, and various endogenous and exogenous nephrotoxins [2,3,4]. Despite considerable advances in basic research and a growing understanding of the underlying mechanisms, no specific therapies beyond renal dialysis and transplantation have emerged for AKI [5,6,7,8]. Therefore, it is crucial to identify druggable targets and develop drugs for AKI.
Microsomal prostaglandin E synthase-2 (mPGES-2), along with mPGES-1 and cytosolic PGES (cPGES), are the three main PGE2 terminal synthases [9, 10]. cPGES is diffusely expressed in all nephron segments, and its loss leads to death during the embryonic period; little is known about its function in various diseases as a PGE2 synthase [11, 12]. In the kidney, mPGES-1 is highly expressed in the collecting duct, and several studies have focused on its role in blood pressure homeostasis and renal hemodynamics and its contribution to different kidney diseases [13,14,15,16]. Although mPGES-1 null mice were not protected from AKI caused by ischemia/reperfusion, they were protected against AKI induced by cisplatin [14], indicating that AKI is a complex syndrome. Whether other PGE2 synthases may participate in the pathogenesis of AKI remains unclear.
mPGES-2, encoded by PTGES2, is the first reported dual-function enzyme. It forms a complex with glutathione (GSH) and heme, catalyzing the conversion of prostaglandin H2 (PGH2) to (12S)-hydroxy-(5Z,8E,10E)-hydroxyheptadecatrienoic acid (HHT) and malondialdehyde (MDA), and only heme-free mPGES-2 with GSH exhibits PGE2 synthetic activity [17, 18]. Although it was originally discovered as a PGE2 synthase, several previous studies, including ours, have demonstrated that mPGES-2 deficiency does not reduce PGE2 production in the kidney, liver, and brown fat under basal or stimulated conditions owing to the rich heme content in these tissues [19,20,21]. In the kidney, the mPGES-2 protein is mainly expressed in the renal cortex and the outer stripe of the outer medulla [11], which are highly susceptible to a series of stimuli inducing AKI. Therefore, we decided to explore the effect of mPGES-2 on AKI.
In the current study, using global and tubule-specific mPGES-2-deficient mice, we aimed to explore the role of mPGES-2 in AKI induced by cisplatin. SZ0232, an mPGES-2 inhibitor, was applied in mouse models of AKI to test the druggable potential of mPGES-2. Additionally, mice were subjected to renal ischemia/reperfusion to further validate the role of mPGES-2 in AKI. This study might aid in the identification of a potential therapeutic target for AKI.
Results
mPGES-2 deficiency protects against cisplatin-induced AKI
To determine the effect of mPGES-2 on AKI, we obtained mPGES-2 wild-type (WT, Ptges2+/+) and mPGES-2-knockout (KO, Ptges2−/−) mice, and found that mPGES-2 deficiency had no significant effect on the expression of mPGES-1 and cPGES, the other two PGE2 synthases (Supplementary Fig. 1A–C). The mPGES-2 WT and KO mice were subjected to cisplatin treatment. We found that, in these mice, the expression of mPGES-2 was decreased, suggesting a potential regulatory role of mPGES-2 in AKI induced by cisplatin (Supplementary Fig. 1D). Further exploration showed that a decreased body weight and an increased kidney weight were seen in mice treated with cisplatin, while no obvious differences were observed in mPGES-2 WT and KO mice (Supplementary Fig. 1E, F). We then assessed renal function by detecting the levels of serum creatinine (SCr) and blood urea nitrogen (BUN). The results showed that mice exposed to cisplatin exhibited significantly increased SCr and BUN (Fig. 1 A, B), indicating that these mice underwent renal impairment. However, mPGES-2 deficiency attenuated the renal dysfunction caused by cisplatin (Fig. 1A, B). In the histological analysis, WT mice treated with cisplatin showed obvious tubular injury characterized by brush border loss, enlargement of the tubular lumen, tubular cell loss, and congestion; these effects were alleviated in mPGES-2 KO mice (Fig. 1C, D). Furthermore, the quantitative reverse transcription-polymerase chain reaction (qRT-PCR) results showed that the mRNA expression of the tubular injury markers kidney injury molecule 1 (Kim-1) and neutrophil gelatinase-associated lipocalin (Ngal) decreased in mPGES-2 KO mice compared to mPGES-2 WT mice under cisplatin (Fig. 1 E, F). These results indicate that mPGES-2 deficiency exerts a protective role in cisplatin-induced AKI.
mPGES-2 deletion ameliorates mitochondrial dysfunction and lipid peroxidation caused by cisplatin
Considering that mPGES-2 significantly modified the morphological changes caused by cisplatin, we further performed transmission electron microscopy to evaluate the ultrastructural changes in the kidney. Interestingly, we found that WT mice treated with cisplatin showed abnormal mitochondrial morphological features, including small size, increased membrane density, and thickened cristae (Fig. 1G–H), changes common in ferroptosis [22, 23]. However, mPGES-2 deficiency resulted in the normalization of mitochondrial cristae and the mitochondrial outer membrane (Fig. 1G–H), suggesting that mPGES-2 might regulate ferroptosis in AKI. Since diminished cellular antioxidants and mitochondrial oxidative stress are also key characteristics of ferroptosis [22], we measured the expression of superoxide dismutase 2, an indicator of mitochondrial antioxidant activity, and found that SOD2 was decreased in WT mice exposed to cisplatin but increased in the presence of mPGES-2 deletion (Fig. 1I). Furthermore, we determined the levels of GSH (a key antioxidant enzyme) and MDA (a product of lipid peroxidation). The results showed that kidneys from mPGES-2 KO mice contained significantly more GSH and less MDA compared to WT mice after treatment with cisplatin (Fig. 1J, K). We also assessed the level of PGE2 and found no difference between mPGES-2 KO and WT mice treated with cisplatin (Fig. 1L). These results suggest that mPGES-2 deficiency has a beneficial effect on maintaining mitochondrial features and antioxidant levels, indicating a possible role in ferroptosis in AKI.
mPGES-2 deletion inhibits renal ferroptosis caused by cisplatin via the p53/SLC7A11/GPX4 axis
To confirm the protective effect of mPGES-2 deficiency against ferroptosis in AKI, the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay, recognized as a measurement of ferroptosis, was used. The results showed that cell death was significantly inhibited in mPGES-2 KO mice compared to that in WT mice under cisplatin, as demonstrated by fewer TUNEL-positive cells (Fig. 2A, B). Furthermore, we performed RNA-seq and found that multiple markers of ferroptosis showed obvious changes, while markers of apoptosis and necrosis showed no significant differences in mPGES-2 KO mice compared to those in WT mice exposed to cisplatin (Fig. 2C; Supplementary Fig. 2A). We further examined the levels of HMGB1 (a necrosis marker), cleaved caspase-3 (an apoptotic marker), as well as GPX4 and SLC7A11 (ferroptosis markers). The expression of HMGB1 and cleaved caspase-3 remained unchanged after mPGES-2 KO when subjected to cisplatin (Supplementary Fig. 2B). However, the levels of GPX4 and SLC7A11 showed a significant upregulation in mPGES-2 KO mice compared to those in WT mice exposed to cisplatin (Fig. 2D, E). Additionally, p53 is recognized as a master regulator of ferroptosis and enhances this form of cell death by targeting SLC7A11 [24, 25]. We thus detected the expression of p53 and found that mPGES-2 deletion significantly inhibited its expression in mice treated with cisplatin (Fig. 2D, E). These results indicate that the protection provided by mPGES-2 deficiency against AKI may be attributed to the inhibition of ferroptosis.
mPGES-2 binds to heme to form a complex, while mPGES-2 deletion results in the release of more free heme. A previous study showed that heme directly bound to p53 and triggered destabilization of p53 protein concurrent with increased p53 ubiquitylation, which could be efficiently blocked by the proteasome inhibitor, MG132 [26]. However, whether mPGES-2 affects p53 proteolysis through dependence on heme, thus regulating ferroptosis in AKI, remains unknown. We then subjected mPGES-2 KO mice to MG132 or a solvent control before cisplatin treatment. The results showed that MG132 significantly aggravated renal dysfunction and morphological damage, and increased the expression of Kim-1 and Ngal in mPGES-2 KO mice treated with cisplatin (Fig. 3A–E). Besides, compared to the control group, MG132 increased cell death as more TUNEL-positive cells were observed in the renal cortex of mPGES-2 KO mice under cisplatin (Fig. 3F, G). Furthermore, we detected the markers of ferroptosis and found that p53 levels significantly increased, whereas SLC7A11 and GPX4 levels decreased, after MG132 treatment in mPGES-2 KO mice exposed to cisplatin (Fig. 3H, I). These results demonstrate that mPGES-2 may inhibit ferroptosis via the regulation of the p53/SLC7A11/GPX4 axis in AKI.
Tubule-specific ablation of mPGES-2 attenuates AKI
To elucidate the role of tubular cell mPGES-2 in AKI, we generated conditional KO mice in which Ptges2 was deleted in tubular cells by using the Cre-LoxP system. By crossbreeding Ptges2 floxed and Ksp-Cre transgenic mice, we obtained tubule-specific mPGES-2 deficiency mice with the genotype Ptges2fl/fl;Ksp-Cre (TKO). Littermates with the genotype Ptges2fl/fl (Flox) were used as controls. Mice were then treated with cisplatin for 72 h and sacrificed for analysis of renal function and morphology. The expression of mPGES-2 in tubules was significantly decreased in Ptges2fl/fl;Ksp-Cre mice, whereas no differences in body weight and kidney weight were observed between Ptges2fl/fl;Ksp-Cre and Ptges2fl/fl mice (Supplementary Fig. 3A–C). However, Ptges2fl/fl;Ksp-Cre mice showed low levels of SCr and BUN, alleviated tubular injury, and decreased expression of Kim-1 and Ngal, compared to Ptges2fl/fl mice (Fig. 4A–F). Furthermore, fewer TUNEL-positive cells were observed in Ptges2fl/fl;Ksp-Cre than in control mice (Fig. 4G, H). An analysis of ferroptosis markers revealed that mPGES-2 deficiency decreased the level of p53, whereas increased the expression of SLC7A11 and GPX4 (Fig. 4I, J; Supplementary Fig. 3D), indicating that mPGES-2 plays a key role in mediating ferroptosis in AKI.
mPGES-2 regulates p53 expression via heme to aggravate ferroptosis induced by cisplatin in HK-2 cells
To confirm the role of mPGES-2 in AKI, HK-2 cells were exposed to cisplatin to mimic AKI in mice. The decreased expression of GPX4 and SLC7A11 and increased expression of p53 were observed, validating the existence of ferroptosis in HK-2 cells under cisplatin (Supplementary Fig. 4A, B). Further, mPGES-2-overexpressing HK-2 cells were generated and treated with cisplatin. Since oxidative stresses caused by ROS can induce rapid depolarization of the mitochondrial membrane potential (MMP, ∆Ψm), we analyzed the effect of mPGES-2 overexpression on the MMP using JC-1 (a cationic probe) staining. Compared to that in control cells, mPGES-2 overexpression aggravated the dissipation of the MMP under cisplatin, as indicated by increased green fluorescence (Supplementary Fig. 5A, B). Furthermore, the production of ROS in HK-2 cells exposed to cisplatin was further increased when mPGES-2 was overexpressed (Supplementary Fig. 5C). These results suggest that mPGES-2 overexpression aggravates the mitochondrial oxidative stress and dysfunction caused by cisplatin.
Mitochondria are the main site of lipid peroxidation, and toxic lipid reactive oxygen species (lipid-ROS) accumulation is a feature of ferroptosis that can be monitored by C11 BODIPY 581/591. We measured the content of lipid-ROS in the mitochondria by co-staining with Mito Tracker Red and C11 BODIPY 581/591 and found that mPGES-2 overexpression significantly enhanced lipid peroxidation induced by cisplatin (Fig. 5A, B). We also knocked down the expression of mPGES-2 in HK-2 cells and found that the decreased MMP caused by cisplatin was prevented (Supplementary Fig. 6A–C). Additionally, mitochondrial ROS production and lipid peroxidation were reduced in mPGES-2 knockdown cells compared to that in the control group when exposed to cisplatin (Supplementary Fig. 6D, E; Supplementary Fig. 7A, B). These results suggest that inhibition of mPGES-2 restores mitochondrial function and antagonizes lipid peroxidation.
To further validate which form of cell death was involved in regulating mPGES-2 in response to injury caused by cisplatin, different concentrations of inhibitors of ferroptosis (ferrostatin-1, Fer-1), apoptosis (Z-VAD-FMK), and necrosis (necrostatin-1) as well as a powerful antioxidant (N-acetyl cysteine, NAC) were used in mPGES-2-overexpressing HK-2 cells. The decreased cell viability induced by cisplatin was significantly restored by ferrostatin-1 in a concentration-dependent manner and partially restored by N-acetyl cysteine. However, Z-VAD-FMK and necrostatin-1 had weaker effects on cell viability than ferrostatin-1 (Fig. 5C). We then detected the expression of key markers of ferroptosis and found that mPGES-2 overexpression decreased GPX4 expression while increasing p53 expression under cisplatin (Fig. 5D, E). We also examined the effect of mPGES-2 on ferroptosis by knocking down mPGES-2 and found that mPGES-2 knockdown increased the expression of GPX4 and SLC7A11, key regulators of ferroptosis, under cisplatin (Supplementary Fig. 7C, D). These results demonstrate that targeting mPGES-2 protects against ferroptosis induced by cisplatin.
mPGES-2 commonly forms a complex with GSH and heme in vivo. mPGES-2 binds with heme, which is an essential co-factor involved in multiple biological processes and diverse diseases [27, 28]. Whether mPGES-2 regulates ferroptosis that is dependent on heme remains unclear. Study showed that heme could bind to the p53 protein, thereby interfering with the p53-DNA interaction and triggering both nuclear export and cytosolic degradation of p53 [26]. Herein, we exposed mPGES-2-overexpressing HK-2 cells to hemin, an analog of heme, and found that hemin reversed the changes in p53, SLC7A11, and GPX4 induced by cisplatin (Fig. 5F, G). These results confirm that mPGES-2 deficiency might regulate the p53/SLC7A11/GPX4 axis via heme, thus inhibiting ferroptosis induced by cisplatin.
The mPGES-2 inhibitor SZ0232 alleviates AKI caused by cisplatin
To further evaluate the translational potential of mPGES-2 in AKI, we used the mPGES-2 inhibitor, SZ0232, discovered by our group [19]. Mice treated with SZ0232 exhibited significantly less cisplatin-induced renal dysfunction and tubular injury, as demonstrated by reduced SCr and BUN levels and a low tubular injury score (Fig. 6A–C). Mice treated with SZ0232 had increased GSH and decreased MDA levels as well as fewer TUNEL-positive cells than control mice under cisplatin (Fig. 6D–F), indicating that SZ0232 inhibits lipid peroxidation and cell death induced by cisplatin. Moreover, we tested the effect of SZ0232 on PGE2 production and found that SZ0232 did not alter the level of PGE2 (Fig. 6G), which occurred in the mPGES-2 knockout mice as well. We also explored the effect of SZ0232 on ferroptosis regulators in HK-2 cells and found that SZ0232 increased the expression of GPX4 and SLC7A11 (Supplementary Fig. 7E, F). These results demonstrate that mPGES-2 may serve as a druggable target for treating AKI by inhibiting ferroptosis.
mPGES-2 inhibition ameliorates AKI induced by renal ischemia/reperfusion
Renal ischemia/reperfusion inevitably occurs during surgery to treat occlusion of the renal arteries or the aorta and is a leading cause of AKI. To further validate the protective role of mPGES-2 in AKI, Ptges2+/+ and Ptges2-/- mice were subjected to renal unilateral ischemia/reperfusion. The expression of mPGES-2 showed no obvious changes under ischemia/reperfusion (Supplementary Fig. 8A, B). However, mPGES-2 deficiency significantly alleviated renal dysfunction and morphological damage, as demonstrated by decreased SCr and BUN levels and less tubular injury (Fig. 7A–C). We also found that mPGES-2 deletion increased the content of GSH but decreased the level of MDA (Fig. 7D, E), indicating that mPGES-2 deficiency exerted a beneficial effect against lipid peroxidation. Furthermore, fewer TUNEL-positive cells were found in the kidneys of Ptges2-/- mice compared to that in Ptges2+/+ mice subjected to renal unilateral ischemia/reperfusion (Fig. 7F). However, mPGES-2 deficiency had no obvious effect on the level of PGE2 when mice were subjected to ischemia/reperfusion (Fig. 7G), as observed in mice under cisplatin. Importantly, similar protective effects of SZ0232 were observed in mice subjected to renal ischemia/reperfusion (Fig. 7H–M). These data suggest that mPGES-2 may serve as a therapeutic option to prevent AKI.
Discussion
AKI is recognized as a heterogeneous syndrome with high morbidity and mortality and a poor prognosis. Several factors, including nephrotoxic drugs, ischemia, insufficient circulating blood volume, and urinary tract obstruction, can cause AKI. Preventive strategies, such as optimizing volume hemodynamics and volume status as well as avoiding nephrotoxins are considered the mainstay of management of early AKI. Nevertheless, kidney transplantation remains the only therapeutic option for severe AKI. To date, there are no specific drugs or therapies to treat AKI. Thus, the identification of new therapeutic targets is desperately needed to overcome the burden of AKI. In the present study, we found that both global and tubule-specific deficiency of mPGES-2 could significantly alleviate renal dysfunction and morphological damage induced by cisplatin or renal ischemia/reperfusion. Importantly, this finding was validated by the use of SZ0232, an mPGES-2 inhibitor. The protective effect of mPGES-2 against AKI might be attributed to the inhibition of ferroptosis via the p53/SLC7A11/GPX4 signaling pathway regulated by heme. Our study demonstrates that mPGES-2 might be a candidate target for inhibiting ferroptosis and restoring renal function in AKI.
AKI is characterized by renal tubular damage, inflammation, and vascular dysfunction. Death of tubular cells is considered the precipitating factor in AKI [29]. Various types of cell death, including apoptosis, necrosis, and necroptosis, are induced in renal tubular epithelial cells [29,30,31,32]. However, for a long time, it was thought that there were only two types of cell death in kidney tubules (necrosis and apoptosis) following cisplatin challenge. Initial research appeared to show that necrosis was the sole one responsible for renal damage caused by cisplatin. Later, Lieberthalet et al. (1996) reported, for the first time, that apoptosis also played a part in cisplatin-induced cell death [30]. Early in 1998, it was reported that exposure to cisplatin resulted in a significant increase in bleomycin-detectable iron in kidney cells, and the use of deferoxamine significantly alleviated kidney injury induced by cisplatin in vivo [31]. More evidence then indicated that ferroptosis was also important in AKI.
Ferroptosis is a form of programmed cell death triggered by iron overload and subsequent overwhelming lipid peroxidation. Ferroptosis appears in cells as reduced mitochondrial volume, increased bilayer membrane density, and a reduction or disappearance of mitochondrial cristae [23]. Ferroptosis-inducing factors can directly or indirectly affect glutathione peroxidase (GPX) through different pathways, resulting in a decrease in antioxidant capacity and an accumulation of lipid-ROS in cells, ultimately leading to oxidative stress-mediated cell death [33, 34]. Both ferrostatin-1 and liproxstatin-1, ferroptosis inhibitors, were reported to attenuate tissue damage in diverse AKI models [35, 36]. Additionally, lipid peroxidation inhibitors, such as antioxidants and iron chelators, were observed to inhibit ferroptosis and alleviate AKI [35, 37, 38]. These findings suggest that targeting ferroptosis may be an alternative and effective option for treating AKI.
In our study, using RNA-seq, we found that markers of apoptosis and necrosis showed no significant change after mPGES-2 knockout. Cleaved caspase-3, a marker of apoptosis, and HMGB1, a marker of necrosis, were detected using western blot, and no differences were observed between mPGES-2 WT and KO mice treated with cisplatin. Notably, mPGES-2 deficiency significantly increased the expression of SLC7A11 and GPX4, key markers of ferroptosis, suggesting a specific role of mPGES-2 deletion in ferroptosis in this experimental setting. However, we cannot entirely exclude the influence of mPGES-2 on other types of cell death, as the level of renal tubular injury and kidney function could also cause secondary responses to alternative forms of cell death and related pathways.
mPGES-2, originally identified as a PGE2 synthase, was reported to form a complex with GSH and heme, thus catalyzing the conversion of PGH2 to produce HHT and MDA, but not PGE2, in the liver, kidney, and brown fat, in both physiological and pathological conditions for rich heme in these tissues. Only heme-free mPGES-2 with GSH exhibits PGE2 synthetic activity. Whether mPGES-2 affects the production of PGE2 in the kidney of mice treated with cisplatin or subjected to ischemia/reperfusion remains unclear. In the present study, we found that a lack of mPGES-2 had little influence on the level of PGE2 in mice but significantly decreased the content of MDA when these animals were exposed to cisplatin or subjected to ischemia/reperfusion. MDA is a well-known marker of lipid peroxidation, which is a characteristic process of ferroptosis. Whether mPGES-2 alleviates AKI via inhibiting ferroptosis remains unknown. In our study, we found that inhibiting mPGES-2 restored renal function and decreased morphological damage, as shown by decreased SCr and BUN levels and less tubular injury. mPGES-2 deficiency inhibited cell death, as demonstrated by a decreased number of TUNEL-positive cells. Further analyses indicated that mPGES-2 inhibition had little effect on the expression of apoptotic and necrotic markers but significantly increased the expression of GPX4 and SLC7A11, markers of ferroptosis. Additionally, mitochondrial dysfunction and oxidative imbalance caused by cisplatin and ischemia/reperfusion were also prevented when mPGES-2 was blocked. Moreover, the decreased viability induced by cisplatin in HK-2 cells was restored by ferrostatin-1, an inhibitor of ferroptosis, in a concentration-dependent manner, whereas inhibitors of apoptosis and necrosis had a weaker effect on the decreased cell viability caused by cisplatin. These results suggest that mPGES-2 might be an important mediator in regulating ferroptosis and a potential therapeutic target for AKI.
mPGES-2 commonly forms a complex with GSH and heme in vivo. Blockage of mPGES-2 will release more free heme, which is necessary for multiple biological processes and diverse diseases [27, 28]. Whether mPGES-2 regulates ferroptosis that is dependent on heme is still unknown. A previous study showed that heme could bind to the p53 protein, thereby interfering with the p53-DNA interaction and triggering both nuclear export and cytosolic degradation of p53, which could be efficiently blocked by the proteasome inhibitor, MG132 [26]. In the present study, we found that acute kidney injury induced by cisplatin was aggravated and the expression of p53 was increased after MG132 treatment. Moreover, mPGES-2 overexpression significantly increased the expression of p53 under cisplatin, effects that were blocked by hemin, an analog of heme. The results suggest that mPGES-2 regulates p53 expression via heme in AKI.
p53 inhibits cystine uptake and sensitizes cells to ferroptosis by repressing the expression of SLC7A11 [25]. SLC7A11 is a cystine/glutamate reverse transporter that can import cystine to synthesize GSH and maintain the function of GPX4 [39]. Blocking SLC7A11 inhibits the import of cystine, leading to GSH depletion and inactivation of phospholipid peroxidase and GPX4. GSH depletion can lead to the iron-dependent accumulation of ROS, especially lipid-ROS that are, themselves, sufficient to kill cells [40, 41]. GPX4 is a central enzyme that utilizes GSH to counteract lipid peroxidation and is essential for maintaining tissue homeostasis and preventing cell death and tissue damage in multiple organs [42, 43]. In the present study, mPGES-2 blockage significantly increased the level of GSH and upregulated the expression of SLC7A11 and GPX4, but inhibited lipid peroxidation. Further, the expression of SLC7A11 and GPX4 were reduced when mPGES-2 was overexpressed, which were reversed by hemin, indicating that mPGES-2 may regulate ferroptosis dependent on heme. Moreover, p53 levels increased, whereas SLC7A11 and GPX4 levels decreased after MG132 treatment in mPGES-2 KO mice exposed to cisplatin. These results demonstrate that mPGES-2 may inhibit ferroptosis via the p53/SLC7A11/GPX4 axis, dependent on heme, in AKI.
In conclusion, the current study provides substantial evidence for the critical function of mPGES-2 in cisplatin- and ischemia/reperfusion-induced AKI (Fig. 8). Genetic blockage of mPGES-2 plays a renoprotective role via inhibition of ferroptosis, which is dependent on heme, to regulate the p53/SLC7A11/GPX4 axis, but not by decreasing PGE2 production. We also applied SZ0232, an mPGES-2 inhibitor, to validate the effect of mPGES-2 on AKI, thereby extending our research work into clinical applications. Thus, targeting mPGES-2 may be a potential strategy for AKI treatment.
Materials and methods
Animal experiments
C57BL/6 J Ptges2+/- and Ptges2flox/+ mice were generated by GemPharmatech Co., Ltd. (Nanjing, China) using CRISPR/Cas9 technology. Ptges2flox/flox mice were bred with Ksp-Cre transgenic mice to obtain tubule-specific mPGES-2-deficient mice (Ptges2fl/fl; Ksp-Cre mice, TKO). Littermates of genotype Ptges2fl/fl (Flox) were used as controls. Eight-week-old male mice were used in all experiments. For the cisplatin-induced AKI model, mice were administered a single intraperitoneal injection of cisplatin (HZ20040813, Hansoh Pharma, 20 mg/kg) and subsequently sacrificed 72 h after injection. Blood samples and renal tissues were collected and analyzed. For the ischemia/reperfusion-induced AKI model, the left kidney was removed while the right kidney pedicle was clamped for 60 min using non-traumatic microvascular clips to induce ischemia; subsequently, the clip was removed to initiate reperfusion. In sham-operated mice, renal pedicles were exposed; however, clamping of the right renal pedicle was not performed. All mice were sacrificed for tissue collection 24 h after reperfusion. In the treatment group, SZ0232 was administered intraperitoneally at a dosage of 1 mg/kg, once a day for 7 days; mice were given a single dose of cisplatin on day 4 and sacrificed on day 7. In the ischemia/reperfusion mice, SZ0232 was administered at a dosage of 1 mg/kg, once a day for 7 days; mice were subjected to ischemia/reperfusion on day 6 and sacrificed 24 h after reperfusion. In the MG132 treatment mice, MG132 was administered intraperitoneally once a day for 5 days; mice were given a single dose of cisplatin on day 2 and sacrificed on day 5. The dosage of MG132 used in our study was 2 mg/kg. MG132 was dissolved in a solvent containing of 75% saline, 10% PEG300, 5% Tween 80, and 10% DMSO. All experimental protocols were conducted following the Guide for the Care and Use of Laboratory Animals of the China Association for Laboratory Animal Science and were ethically approved by the Institutional Animal Care and Use Committee of Xuzhou Medical University (202011A137).
Morphological evaluation
For hematoxylin and eosin (H&E) staining, kidney samples were collected, fixed with 4% paraformaldehyde, and embedded in paraffin. Paraffin sections were prepared, deparaffinized, and stained with H&E. Finally, xylene and ethanol were used for dehydration, and neutral gum was used for sealing. Images were captured systematically using an Olympus BX43F microscope. The tubular injury was assessed in H&E-stained sections using a semiquantitative scale, which graded the percentage of damaged tubules: 0, no damage; 1, less than 25% damage; 2, 25–50% damage; 3, 50–75% damage; 4, more than 75% damage. The criteria of tubular damage included the loss of brush border, tubular dilation, cast formation, and cell lysis, as previously described [44, 45].
For transmission electron microscopy (TEM), fresh kidney cortex samples were collected and immediately fixed in 2.5% glutaraldehyde. Samples were then prepared and analyzed by Servicebio Technology Co., Ltd.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 8. All data are presented as mean ± SEM. Data involving only two groups were analyzed using a two-tailed unpaired Student’s t-test. When more than two groups were compared, the data were analyzed using one-way ANOVA with Tukey’s test. P values < 0.05 were considered significant.
Data availability
All data are available in the manuscript or supplementary files. Additional source data are available from the corresponding author upon reasonable request. RNA-seq data were deposited in NCBI Sequence Read Archive (SRA) under the accession number PRJNA838832.
References
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7:52.
Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394:1949–64.
Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380:2146–55.
Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891.
Vanmassenhove J, Kielstein J, Jorres A, Biesen WV. Management of patients at risk of acute kidney injury. Lancet. 2017;389:2139–51.
Pickkers P, Darmon M, Hoste E, Joannidis M, Legrand M, Ostermann M, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Med. 2021;47:835–50.
Jentzer JC, Bihorac A, Brusca SB, Del Rio-Pertuz G, Kashani K, Kazory A, et al. Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. J Am Coll Cardiol. 2020;76:1084–101.
Yang Y, Song M, Liu Y, Liu H, Sun L, Peng Y, et al. Renoprotective approaches and strategies in acute kidney injury. Pharmacol Ther. 2016;163:58–73.
Kudo I, Murakami M. Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol. 2005;38:633–8.
Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci. 1999;96:7220–5.
Wang J, Liu M, Zhang X, Yang G, Chen L. Physiological and pathophysiological implications of PGE2 and the PGE2 synthases in the kidney. Prostaglandins Other Lipid Mediat. 2018;134:1–6.
Lovgren AK, Kovarova M, Koller BH. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis. Mol Cell Biol. 2007;27:4416–30.
Schneider A, Zhang Y, Zhang M, Lu WJ, Rao R, Fan X, et al. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int. 2004;65:1205–13.
Jia Z, Wang N, Aoyagi T, Wang H, Liu H, Yang T. Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int. 2011;79:77–88.
Jia Z, Zhang A, Zhang H, Dong Z, Yang T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res. 2006;99:1243–51.
Jia Z, Wang H, Yang T. Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction. Hypertension. 2012;59:122–8.
Takusagawa F. Microsomal prostaglandin E synthase type 2 (mPGES2) is a glutathione-dependent heme protein, and dithiothreitol dissociates the bound heme to produce active prostaglandin E2 synthase in vitro. J Biol Chem. 2013;288:10166–75.
Yamada T, Takusagawa F. PGH2 degradation pathway catalyzed by GSH-heme complex bound microsomal prostaglandin E2 synthase type 2: the first example of a dual-function enzyme. Biochemistry. 2007;46:8414–24.
Zhong D, Wan Z, Cai J, Quan L, Zhang R, Teng T, et al. mPGES-2 blockade antagonizes β-cell senescence to ameliorate diabetes by acting on NR4A1. Nat. Metab. 2022; 4:269–83.
Sun Y, Jia Z, Yang G, Kakizoe Y, Liu M, Yang KT, et al. mPGES-2 deletion remarkably enhances liver injury in streptozotocin-treated mice via induction of GLUT2. J Hepatol. 2014;61:1328–36.
Jania LA, Chandrasekharan S, Backlund MG, Foley NA, Snouwaert J, Wang IM, et al. Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E-2 biosynthesis. Prostag Oth Lipid M. 2009;88:73–81.
Ni L, Yuan C, Wu X. Targeting ferroptosis in acute kidney injury. Cell Death Dis. 2022;13:182.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
Liu Y, Gu W. p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death Differ. 2022; 29: 895–910.
Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57–62.
Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep. 2014;7:180–93.
Chiabrando D, Vinchi F, Fiorito V, Mercurio S, Tolosano E. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front Pharmacol. 2014;5:61.
Shimizu T, Lengalova A, Martinek V, Martinkova M. Heme: emergent roles of heme in signal transduction, functional regulation and as catalytic centres. Chem Soc Rev. 2019;48:5624–57.
Takaori K, Nakamura J, Yamamoto S, Nakata H, Sato Y, Takase M, et al. Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis. J Am Soc Nephrol. 2016;27:2393–406.
Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol. 1996;270:F700–8.
Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998;53:394–401.
Sanz AB, Sanchez-Nino MD, Ramos AM, Ortiz A. Regulated cell death pathways in kidney disease. Nat Rev Nephrol. 2023;19:281–99.
Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180–91.
Hadian K, Stockwell BR. SnapShot: Ferroptosis. Cell. 2020;181:1188–e1.
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369–79.
Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco S, Cannata-Ortiz P, Sanchez-Nino MD, et al. Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. J Am Soc Nephrol. 2017;28:218–29.
Mishima E, Sato E, Ito J, Yamada KI, Suzuki C, Oikawa Y, et al. Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. J Am Soc Nephrol. 2020;31:280–96.
Adedoyin O, Boddu R, Traylor A, Lever JM, Bolisetty S, George JF, et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am J Physiol Renal Physiol. 2018;314:F702–F14.
Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17:2054–81.
Zheng J, Conrad M. The Metabolic Underpinnings of Ferroptosis. Cell Metab. 2020;32:920–37.
Jang S, Chapa-Dubocq XR, Tyurina YY, St Croix CM, Kapralov AA, Tyurin VA, et al. Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes. Redox Biol. 2021;45:102021.
Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016;26:165–76.
Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? Mol Psych. 2017;22:328–35.
Zhang D, Liu Y, Wei Q, Huo Y, Liu K, Liu F, et al. Tubular p53 regulates multiple genes to mediate AKI. J Am Soc Nephrol. 2014;25:2278–89.
Xu S, Jia P, Fang Y, Jin J, Sun Z, Zhou W, et al. Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation. Kidney Int. 2022;101:987–1002.
Funding
This work was supported by the National Natural Science Foundation of China 81603179, 82000683; the China Postdoctoral Science Special Foundation 2018T110555; the Key Project of Natural Science Research in Jiangsu Universities 21KJA350002; Jiangsu Province Innovative and Entrepreneurial Team Program; Jiangsu Research Innovation Program for College Graduates KYCX23_2966; the Natural Science Research Project of Jiangsu Universities 20KJB310023; the Xuzhou Science and Technology Plan Project KC20150; and the Fusion Innovation Project of Xuzhou Medical University XYRHCX2021010.
Author information
Authors and Affiliations
Contributions
YS, DZ and ZJ conceived and designed the study; LQ, DZ, CH, JC, RQ and TL performed the experiments; DZ, YS, LQ, CH, JC, CY, DS and ZJ analyzed and interpreted the results; DZ, YS and ZJ drafted and revised the manuscript. All authors approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by Professor Boris Zhivotovsky
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhong, D., Quan, L., Hao, C. et al. Targeting mPGES-2 to protect against acute kidney injury via inhibition of ferroptosis dependent on p53. Cell Death Dis 14, 710 (2023). https://doi.org/10.1038/s41419-023-06236-7
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-023-06236-7
- Springer Nature Limited
This article is cited by
-
Sodium Selenite Prevents Matrine-Induced Nephrotoxicity by Suppressing Ferroptosis via the GSH-GPX4 Antioxidant System
Biological Trace Element Research (2024)
-
The role of ferroptosis in acute kidney injury: mechanisms and potential therapeutic targets
Molecular and Cellular Biochemistry (2024)